<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312470184</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312470184</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Single nucleotide polymorphism of <italic>CD40</italic> region and the risk of systemic lupus erythematosus</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Piotrowski</surname><given-names>P</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312470184">1</xref>
<xref ref-type="aff" rid="aff3-0961203312470184">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lianeri</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312470184">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wudarski</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff2-0961203312470184">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Olesińska</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff2-0961203312470184">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Jagodziński</surname><given-names>PP</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312470184">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203312470184"/>
</contrib>
</contrib-group>
<aff id="aff1-0961203312470184"><label>1</label>Department of Biochemistry and Molecular Biology, Poznań University of Medical Sciences, Poland</aff>
<aff id="aff2-0961203312470184"><label>2</label>Institute of Rheumatology, Warsaw, Poland</aff>
<aff id="aff3-0961203312470184"><label>3</label>Mossakowski Medical Research Centre Polish Academy of Sciences, Warsaw, Poland</aff>
<author-notes>
<corresp id="corresp1-0961203312470184">Pawe<italic>ł</italic> P. Jagodzinski, Department of Biochemistry and Molecular Biology, Poznań University of Medical Sciences, 6 Święcickiego St, 60-781 Poznań, Poland. Email: <email>pjagodzi@am.poznan.pl</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>3</issue>
<fpage>233</fpage>
<lpage>237</lpage>
<history>
<date date-type="received"><day>20</day><month>4</month><year>2012</year></date>
<date date-type="accepted"><day>6</day><month>11</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012. Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>There is one study on the association of the <italic>CD40</italic> G &gt; T (rs4810485) single nucleotide polymorphism (SNP) as a risk factor of systemic lupus erythematosus (SLE). Therefore, we studied the prevalence of the <italic>CD40</italic> G &gt; T SNP in patients with SLE (<italic>n</italic> = 261) and controls (<italic>n</italic> = 545) in a Polish population. We did not find significant differences between the CD40 G &gt; T genotype and allele frequency in patients with SLE and healthy individuals. However, the frequency of the <italic>CD40</italic> TT and GT genotypes was statistically different between patients with arthritis and neurologic manifestations and patients without these symptoms (OR = 0.2009 (95% CI = 0.07547–0.5348, <italic>p</italic> = 0.0004, <italic>p</italic><sub>corr</sub> = 0.0068) and OR = 0.2876 (95% CI = 0.1371–0.6031, <italic>p</italic> = 0.0005, <italic>p</italic><sub>corr</sub> = 0.0085) respectively). Our observations indicate that the <italic>CD40</italic> T variant might be negatively associated with some clinical disease manifestations in patients with SLE.</p>
</abstract>
<kwd-group>
<kwd>Anti-DNA antibodies</kwd>
<kwd>Systemic Lupus Erythematosus</kwd>
<kwd>arthritis</kwd>
<kwd>neurologic manifestations</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203312470184" sec-type="intro"><title>Introduction</title>
<p>Systemic lupus erythematosus (SLE) is a multifactorial systemic autoimmune disease characterized by the development of an immune response directed against the body’s own tissues.<sup><xref ref-type="bibr" rid="bibr1-0961203312470184">1</xref></sup> Despite the fact that SLE has been intensively studied, the underlying cause of this autoimmune disease remains elusive.<sup><xref ref-type="bibr" rid="bibr1-0961203312470184">1</xref></sup> The interactions between environmental and genetic factors in the development of SLE have been well documented.<sup><xref ref-type="bibr" rid="bibr2-0961203312470184">2</xref>,<xref ref-type="bibr" rid="bibr3-0961203312470184">3</xref></sup> The genetic risk factors mainly include many genes related to the immune system.<sup><xref ref-type="bibr" rid="bibr4-0961203312470184">4</xref>–</sup><sup><xref ref-type="bibr" rid="bibr7-0961203312470184">7</xref></sup> Genome wide association studies have demonstrated that numerous genetic loci exhibit low-to-moderate susceptibility for SLE.<sup><xref ref-type="bibr" rid="bibr4-0961203312470184">4</xref>,<xref ref-type="bibr" rid="bibr7-0961203312470184">7</xref></sup> The most significant genes increasing the risk of SLE are situated in the HLA locus; however, other genes encoding molecules regulating the function of immune cells also contribute to SLE.<sup><xref ref-type="bibr" rid="bibr4-0961203312470184">4</xref>–</sup><sup><xref ref-type="bibr" rid="bibr7-0961203312470184">7</xref></sup> One of these genes, encoding CD40, has been identified as a genetic risk factor for rheumatoid arthritis (RA) and is also recognized as a risk factor for SLE.<sup><xref ref-type="bibr" rid="bibr8-0961203312470184">8</xref>,<xref ref-type="bibr" rid="bibr9-0961203312470184">9</xref></sup></p>
<p>CD40 is a member of the tumor necrosis factor (TNF) receptor superfamily that was originally identified as both a B-cell costimulatory receptor and a tumor antigen presented in bladder carcinoma.<sup><xref ref-type="bibr" rid="bibr10-0961203312470184">10</xref></sup> CD40 is presented constitutively on the surface of B cells, dendritic cells, and macrophages, and under certain conditions can also be presented on monocytes, basophils, eosinophils, and T cells.<sup><xref ref-type="bibr" rid="bibr10-0961203312470184">10</xref></sup> Moreover, CD40 is located on the surface of non-immune cells such as endothelial, neuronal, epithelial, and smooth muscle cells and keratinocytes.<sup><xref ref-type="bibr" rid="bibr11-0961203312470184">11</xref>–</sup><sup><xref ref-type="bibr" rid="bibr13-0961203312470184">13</xref></sup> CD40 plays an important role in T-cell-dependent B-cell humoral responses, regulation of cytokines, growth factor production in monocytes, and modulation of adhesion molecule density on the endothelial cell surface.<sup><xref ref-type="bibr" rid="bibr13-0961203312470184">13</xref></sup> CD40 may be involved in the pathogenesis and exacerbation of different human autoimmune diseases, including SLE.<sup><xref ref-type="bibr" rid="bibr14-0961203312470184">14</xref></sup> The pathogenic effect of CD40–CD40 ligand (CD40L) interactions has been well determined in both the murine SLE model and human SLE.<sup><xref ref-type="bibr" rid="bibr15-0961203312470184">15</xref>,<xref ref-type="bibr" rid="bibr16-0961203312470184">16</xref></sup> Therefore, the single nucleotide polymorphisms (SNPs) modulating <italic>CD40</italic> gene expression may increase the risk of autoimmune disease.</p>
<p>There is one study on the association of the <italic>CD40</italic> G &gt; T (rs4810485) SNP with an increased risk for SLE.<sup><xref ref-type="bibr" rid="bibr9-0961203312470184">9</xref></sup> Therefore, we aimed to study whether <italic>CD40</italic> G &gt; T (rs4810485) can be a genetic risk factor of SLE in the Polish population. Because SLE is a heterogeneous disease, we also assessed the association of this SNP with various clinical symptoms of SLE.</p>
</sec>
<sec id="sec2-0961203312470184" sec-type="methods"><title>Patients and methods</title>
<sec id="sec3-0961203312470184" sec-type="subjects"><title>Patients and controls</title>
<p>Data for 261 women fulfilling the American College of Rheumatology Classification criteria for SLE<sup><xref ref-type="bibr" rid="bibr17-0961203312470184">17</xref>–</sup><sup><xref ref-type="bibr" rid="bibr18-0961203312470184">18</xref></sup> were sequentially collected for the study at the Institute of Rheumatology in Warsaw, Poland (<xref ref-type="table" rid="table1-0961203312470184">Table 1</xref>). Controls included 545 unrelated healthy volunteers and healthy women selected during medical examination at the Institute of Mother and Child, Warsaw. Women with SLE and controls were of Polish Caucasian origin and of a similar age. The mean age of SLE patients at diagnosis was 36 ± 9 years, and of controls 35 ± 8 years. All participating individuals provided written consent. The study procedures were approved by the Local Ethical Committee of Poznań University of Medical Sciences.
<table-wrap id="table1-0961203312470184" position="float"><label>Table 1</label><caption><p>Frequency of the <italic>CD40</italic> G &gt; T (rs4810485) genotypes among SLE patients with different clinical manifestations</p></caption>
<graphic alternate-form-of="table1-0961203312470184" xlink:href="10.1177_0961203312470184-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Characteristic</th>
<th colspan="4">Genotype distribution<hr/></th>
</tr>
<tr><th>GG (158)<sup><xref ref-type="table-fn" rid="table-fn1-0961203312470184">a</xref></sup></th>
<th>GT (95)<sup><xref ref-type="table-fn" rid="table-fn1-0961203312470184">a</xref></sup></th>
<th>TT (8)<sup><xref ref-type="table-fn" rid="table-fn1-0961203312470184">a</xref></sup></th>
<th>Odds ratio (95% CI), <italic>p</italic><sup><xref ref-type="table-fn" rid="table-fn1-0961203312470184">c</xref></sup></th>
</tr></thead>
<tbody align="left">
<tr>
<td>Malar rash</td>
<td>85</td>
<td>49</td>
<td>4</td>
<td/>
</tr>
<tr>
<td>Discoid rash</td>
<td>47</td>
<td>28</td>
<td>2</td>
<td/>
</tr>
<tr>
<td>Photosensitivity</td>
<td>73</td>
<td>43</td>
<td>4</td>
<td/>
</tr>
<tr>
<td>Oral or nasopharyngeal</td>
<td>63</td>
<td>37</td>
<td>3</td>
<td/>
</tr>
<tr>
<td>Arthritis</td>
<td>32</td>
<td>4</td>
<td>1</td>
<td>0.2009 (0.07547–0.5348,</td>
</tr>
<tr>
<td>Serositis</td>
<td>17</td>
<td>10</td>
<td>1</td>
<td><italic>p</italic> = 0.0004)<sup><xref ref-type="table-fn" rid="table-fn1-0961203312470184">b</xref></sup></td>
</tr>
<tr>
<td>Renal</td>
<td>77</td>
<td>45</td>
<td>5</td>
<td/>
</tr>
<tr>
<td>Neurologic</td>
<td>43</td>
<td>9</td>
<td>1</td>
<td>0.2876 (0.1371–0.6031, <italic>p</italic> = 0.0005)<sup><xref ref-type="table-fn" rid="table-fn1-0961203312470184">b</xref></sup></td>
</tr>
<tr>
<td>Headache</td>
<td>12</td>
<td>6</td>
<td>1</td>
<td/>
</tr>
<tr>
<td>Mood disorders</td>
<td>11</td>
<td>6</td>
<td>0</td>
<td/>
</tr>
<tr>
<td>Cerebrovascular symptoms</td>
<td>7</td>
<td>3</td>
<td>1</td>
<td/>
</tr>
<tr>
<td>Mononeuropathy</td>
<td>5</td>
<td>4</td>
<td>0</td>
<td/>
</tr>
<tr>
<td>Anxiety disorder</td>
<td>4</td>
<td>1</td>
<td>0</td>
<td/>
</tr>
<tr>
<td>Cognitive impairment</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td/>
</tr>
<tr>
<td>Transverse myelitis</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td/>
</tr>
<tr>
<td>Hematologic</td>
<td>53</td>
<td>31</td>
<td>4</td>
<td/>
</tr>
<tr>
<td>Immunologic</td>
<td>73</td>
<td>43</td>
<td>4</td>
<td/>
</tr>
<tr>
<td>Antinuclear antibody</td>
<td>158</td>
<td>95</td>
<td>8</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203312470184"><label>a</label><p>The absolute number of positive patients for GG, GT, and TT genotypes, respectively.</p></fn>
<fn id="table-fn2-0961203312470184"><p>Comparison of genotypes <sup>b</sup>(GT or TT vs. GG genotype) between patients with and patients ithout a particular manifestation was performed by <sup>c</sup>Fischer test.</p></fn>
<fn id="table-fn3-0961203312470184"><p>CI: confidence interval; SLE: systemic lupus erythematosus.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec4-0961203312470184"><title>Genotyping</title>
<p>DNA was isolated from peripheral leukocytes using a standard salting out procedure. Identification of the <italic>CD40</italic> (rs4810485) polymorphic variant was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). PCR was conducted employing primer pair 5′ TGTATTTTTGTAGTTCCTCATTCT 3′ and 5′ TTCCCTTGCTTTCCTTGATACC 3′. The PCR-amplified fragments of <italic>CD40</italic>, which were 157 bp in length, were isolated and digested with the endonuclease MspI (C/CGG) (New England BioLabs, Ipswich, USA). The <italic>CD40</italic> G allele was cleaved into 105 bp and 52 bp fragments, whereas the <italic>CD40</italic> T allele remained uncut. DNA fragments were separated by electrophoresis on 3% agarose gel and visualized by ethidium bromide staining. The <italic>CD40</italic> polymorphism was confirmed by repeated PCR-RFLP. Moreover, the restriction analysis was confirmed by commercial sequencing analysis.</p>
</sec>
<sec id="sec5-0961203312470184"><title>Statistical analysis</title>
<p>The prevalence of genotypes in patients and controls was examined for deviation from Hardy–Weinberg equilibrium using exact and log likelihood ratio χ<sup>2</sup> tests (<ext-link ext-link-type="uri" xlink:href="http://ihg.gsf.de/cgi-bin/hw/hwa1.pl">http://ihg.gsf.de/cgi-bin/hw/hwa1.pl</ext-link>). The polymorphism was tested for association with SLE incidence using the χ<sup>2</sup> test for trend (<italic>p</italic><sub>trend</sub>). The χ<sup>2</sup> test was employed to examine differences in genotypic and allelic distribution between patients and controls, and a <italic>p</italic> value &lt;0.05 was considered statistically significant. The odds ratio (OR) and 95% confidence intervals (95% CI) were calculated. The association of the <italic>CD40 G</italic> &gt; T polymorphism with clinical manifestations and the presence of autoantibodies was evaluated by Fischer test. The Bonferroni correction for multiple comparisons was used and both <italic>p</italic> values, before (<italic>p</italic>) and after correction (<italic>p</italic><sub>corr</sub>), were evaluated.</p>
</sec>
</sec>
<sec id="sec6-0961203312470184" sec-type="results"><title>Results</title>
<sec id="sec7-0961203312470184"><title>Prevalence of CD40 G &gt; T genotypes and alleles in SLE patients and controls</title>
<p>Genotype evaluation of the <italic>CD40 G</italic> &gt; T (rs4810485) polymorphism did not demonstrate significant aberration from the Hardy–Weinberg equilibrium in the patient or control groups.</p>
<p>There was an increased frequency of the TT genotype in controls as compared with patients with SLE; however, these differences were not significant (OR = 0.5626 (95% CI = 0.2535–1.249, <italic>p</italic> = 0.1521)). We also observed an increased frequency of the TT and GT genotypes in controls compared with patients with SLE, but these differences were also not significant (OR = 0.8535 (95% CI = 0.6319–1.153, <italic>p</italic> = 0.3015)) (<xref ref-type="table" rid="table2-0961203312470184">Table 2</xref>). There was also no significant change in the frequency of the T allele between the controls and patients (OR = 0.8408 (95% CI = 0.6540–1.081, <italic>p</italic> = 0.1758)) (<xref ref-type="table" rid="table2-0961203312470184">Table 2</xref>). The <italic>p</italic> value of the χ<sup>2</sup> test for the trend observed for the <italic>CD40 G</italic> &gt; T (rs4810485) polymorphism was also not statistically significant (<italic>p</italic><sub>trend</sub> = 0.1654).
<table-wrap id="table2-0961203312470184" position="float"><label>Table 2</label><caption><p>Frequency of the <italic>CD40</italic> G &gt; T (rs4810485) genotypes and alleles in SLE patients and controls</p></caption>
<graphic alternate-form-of="table2-0961203312470184" xlink:href="10.1177_0961203312470184-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>CD40 G &gt; T (rs4810485)</th>
<th>SLE <italic>n</italic> = 261</th>
<th>Controls <italic>n</italic> = 545</th>
<th>OR</th>
<th>95% CI</th>
<th><italic>p</italic>-value<sup><xref ref-type="table-fn" rid="table-fn4-0961203312470184">d</xref></sup></th>
<th><italic>p</italic><sub>trend</sub></th>
</tr></thead>
<tbody align="left">
<tr>
<td>Genotype frequency</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> GG</td>
<td>158 (0.61)</td>
<td>309 (0.57)</td>
<td/>
<td/>
<td/>
<td>0.1654</td>
</tr>
<tr>
<td> GT</td>
<td>95 (0.36)</td>
<td>207 (0.38)</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> TT</td>
<td>8 (0.03)</td>
<td>29 (0.05)</td>
<td>0.5626<sup><xref ref-type="table-fn" rid="table-fn4-0961203312470184">a</xref></sup></td>
<td>(0.2535–1.249)<sup><xref ref-type="table-fn" rid="table-fn4-0961203312470184">a</xref></sup></td>
<td>0.1521<sup><xref ref-type="table-fn" rid="table-fn4-0961203312470184">a</xref></sup></td>
<td/>
</tr>
<tr>
<td> GT + TT</td>
<td>103 (0.39)</td>
<td>236 (0.43)</td>
<td>0.8535<sup><xref ref-type="table-fn" rid="table-fn4-0961203312470184">b</xref></sup></td>
<td>(0.6319–1.153)<sup><xref ref-type="table-fn" rid="table-fn4-0961203312470184">b</xref></sup></td>
<td>0.3015<sup><xref ref-type="table-fn" rid="table-fn4-0961203312470184">b</xref></sup></td>
<td/>
</tr>
<tr>
<td>Minor allele frequency</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> T</td>
<td>0.21</td>
<td>0.24</td>
<td>0.8408<sup><xref ref-type="table-fn" rid="table-fn4-0961203312470184">c</xref></sup></td>
<td>0.6540–1.081<sup><xref ref-type="table-fn" rid="table-fn4-0961203312470184">c</xref></sup></td>
<td>0.1758<sup><xref ref-type="table-fn" rid="table-fn4-0961203312470184">c</xref></sup></td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0961203312470184"><p>The odds ratio (OR) was calculated for patients <sup>a</sup>(TT vs. G/T and GG genotype), <sup>b</sup>(TT and GT vs. GG genotype). We also determined the OR for the patients’ minor allele; <sup>c</sup>(T allele vs. G allele); <sup>d</sup>χ<sup>2</sup> test.</p></fn>
<fn id="table-fn5-0961203312470184"><p>CI: confidence interval; SLE: systemic lupus erythematosus.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec8-0961203312470184"><title>Association of CD40 G &gt; T genotypes with clinical symptoms of SLE</title>
<p>The most significant <italic>p</italic> value for differences in the distribution of <italic>CD40</italic> TT and GT vs. GG genotype was found in SLE patients with arthritis and neurologic manifestations (OR = 0.2009 (95% CI = 0.07547–0.5348, <italic>p</italic> = 0.0004, <italic>p</italic><sub>corr</sub> = 0.0096) and OR = 0.2876 (95% CI = 0.1371–0.6031, <italic>p</italic> = 0.0005, <italic>p</italic><sub>corr</sub> = 0.012), respectively) (<xref ref-type="table" rid="table1-0961203312470184">Table 1</xref>). However, there was no association of the <italic>CD40</italic> G &gt; T polymorphism with subtypes of neurologic manifestations (<xref ref-type="table" rid="table1-0961203312470184">Table 1</xref>). Moreover, we did not find a significant association between the <italic>CD40</italic> G &gt; T polymorphism and the presence of anti-double-stranded (ds)DNA, anti-Smith, anti-snRNP, anti-Ro, anti-Scl-70 or anti-phospholipid antibodies (Abs) (not shown).</p>
</sec>
</sec>
<sec id="sec9-0961203312470184" sec-type="discussion"><title>Discussion</title>
<p>In SLE patients, immune cells display abnormal signaling, defective gene expression, reduced T-cell cytotoxicity, and increased humoral response.<sup><xref ref-type="bibr" rid="bibr19-0961203312470184">19</xref>,<xref ref-type="bibr" rid="bibr20-0961203312470184">20</xref></sup> CD40L is one of the molecules of which skewed levels in T cells may contribute to the abnormal humoral response occurring in SLE.<sup><xref ref-type="bibr" rid="bibr21-0961203312470184">21</xref></sup> Binding of CD40L to CD40 provides an elementary stimulus for B cell activation, proliferation, immunoglobulin production, isotype switching, and increased expression of other costimulatory molecules.<sup><xref ref-type="bibr" rid="bibr22-0961203312470184">22</xref>,<xref ref-type="bibr" rid="bibr23-0961203312470184">23</xref></sup> Thus, CD40 can be one of the candidate molecules involved in the activation of T and B cells and leading to pathology in autoimmune disorders.<sup><xref ref-type="bibr" rid="bibr14-0961203312470184">14</xref></sup> The pathogenic contribution of CD40 has been shown in autoimmune diabetes and thyroiditis, inflammatory bowel disease, psoriasis, multiple sclerosis, RA, and SLE.<sup><xref ref-type="bibr" rid="bibr14-0961203312470184">14</xref></sup> Koshy et al<italic>.</italic> (1996) demonstrated the role of CD40–CD40L interaction in the pathogenesis of SLE. They showed that SLE T cells cocultured with target B cells induced greater B-cell surface CD80 expression than did activated T cells from healthy individuals.<sup><xref ref-type="bibr" rid="bibr21-0961203312470184">21</xref></sup> Duffau et al<italic>.</italic> (2010) found that SLE platelets released CD40L, which interacted with CD40 of plasmacytoid dendritic cells, which subsequently secreted interferon-alpha.<sup><xref ref-type="bibr" rid="bibr24-0961203312470184">24</xref></sup> Additionally to these findings, Wang et al<italic>.</italic> (2002) showed that the action of combined short-term CTLA4Ig and anti-CD40 Abs resulted in prolonged suppression of disease onset in murine SLE models.<sup><xref ref-type="bibr" rid="bibr15-0961203312470184">15</xref></sup> Furthermore, Boumpas et al<italic>.</italic> (2003) demonstrated that using humanized anti-CD40L antibody in patients with proliferative lupus nephritis decreased the levels of anti-double-stranded (ds) DNA antibodies, increased the C3 concentration, and decreased hematuria.<sup><xref ref-type="bibr" rid="bibr16-0961203312470184">16</xref></sup></p>
<p>The <italic>CD40</italic> gene is located in a region (20q11–13) that has been suggested as a locus associated with SLE in European Caucasians, Mexican Americans, and African Americans.<sup><xref ref-type="bibr" rid="bibr25-0961203312470184">25</xref>,<xref ref-type="bibr" rid="bibr26-0961203312470184">26</xref></sup> However, in our investigation, we did not find an association between the <italic>CD40 G</italic> &gt; T (rs4810485) SNP and susceptibility to SLE. Our observations are contradictory to the findings of Vazgiourakis et al<italic>.</italic> (2011), who demonstrated an association of the <italic>CD40 G</italic> &gt; T (rs4810485) polymorphism with SLE in Greek and Turkish Mediterranean populations.<sup><xref ref-type="bibr" rid="bibr9-0961203312470184">9</xref></sup></p>
<p>The distinction between the effect of the <italic>CD40 G</italic> &gt; T (rs4810485) genotype on the risk of SLE in Greek and Turkish populations and our populations may result from genetic heterogeneity, size of the studied groups, and different exposure of the populations to environmental factors.</p>
<p>We also did not find a significant association between the <italic>CD40</italic> G &gt; T polymorphism and the presence of anti-dsDNA, anti-Smith, anti-snRNP, anti-Ro, anti-Scl-70, or anti-phospholipid Abs. These negative associations might result from the relatively small size of the studied group of SLE patients and from the fact that only some of those patients tested positive for the analyzed autoantibodies.</p>
<p>However, we found that the <italic>CD40</italic> T (rs4810485) gene variant in SLE patients may have negative associations with neurologic manifestations and arthritis. The CD40 T protein variant might reduce the interaction between the CD40–CD40L pair, thereby acting to induce T-cell-mediated humoral responses leading to decreased risk of arthritis in SLE.<sup><xref ref-type="bibr" rid="bibr9-0961203312470184">9</xref>,<xref ref-type="bibr" rid="bibr27-0961203312470184">27</xref>,<xref ref-type="bibr" rid="bibr28-0961203312470184">28</xref></sup> Vazgiourakis et al. (2011) demonstrated that CD14<sup>+</sup> monocytes and CD19<sup>+</sup> B cells bearing the GT and TT genotypes exhibited significantly reduced CD40 mRNA and protein levels compared with the GG genotype.<sup><xref ref-type="bibr" rid="bibr9-0961203312470184">9</xref></sup> Moreover, interruption of the CD40–CD40L interaction has been considered a useful therapeutic approach in RA and other autoimmune diseases.<sup><xref ref-type="bibr" rid="bibr27-0961203312470184">27</xref>,<xref ref-type="bibr" rid="bibr28-0961203312470184">28</xref></sup> The contribution of the <italic>CD40</italic> T variant to the reduction of neurologic manifestations might also result from lower CD40 densities on the surface of either neuronal or immune cells and decreased inflammatory stages.</p>
<p>To date, the <italic>CD40 G</italic> &gt; T (rs4810485) SNP has also been recognized as a risk factor of RA, psoriasis, Behcet’s disease, and breast cancer in Chinese Han women.<sup><xref ref-type="bibr" rid="bibr8-0961203312470184">8</xref>,<xref ref-type="bibr" rid="bibr29-0961203312470184">29</xref>–</sup><sup><xref ref-type="bibr" rid="bibr31-0961203312470184">31</xref></sup> Moreover, other <italic>CD40</italic> SNPs have been found to contribute to Crohn’s and Graves’ diseases, as well as to manifestations of biopsy-proven giant cell arteritis.<sup><xref ref-type="bibr" rid="bibr32-0961203312470184">32</xref>–</sup><sup><xref ref-type="bibr" rid="bibr34-0961203312470184">34</xref></sup> The <italic>CD40</italic> gene variants also have an effect on the development of lymphomas, chronic obstructive pulmonary disease, and some disorders related to the coronary arteries.<sup><xref ref-type="bibr" rid="bibr35-0961203312470184">35</xref>–</sup><sup><xref ref-type="bibr" rid="bibr38-0961203312470184">38</xref></sup></p>
<p>Our study did not confirm the <italic>CD40 G</italic> &gt; T (rs4810485) SNP as a risk factor of SLE in the Polish population, but we found an association of this gene variant with neurologic manifestations and the presence of arthritis in SLE patients. However, to study the detailed role of the <italic>CD40</italic> G &gt; T (rs4810485) polymorphism in SLE, this study should be replicated in larger and independent cohorts.</p>
</sec>
</body>
<back><ack>
<title>Acknowledgements</title>
<p>This study was supported by grant No 502-01-01124182-07474, Poznań University of Medical Sciences. The technical assistance of Ms Monika Świerczewska is gratefully acknowledged.</p>
</ack>
<sec id="sec10-0961203312470184">
<title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec11-0961203312470184">
<title>Conflicts of interest statement</title>
<p>The authors have no conflicts of interest to declare.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312470184"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sekigawa</surname><given-names>I</given-names></name><name><surname>Naito</surname><given-names>T</given-names></name><name><surname>Hira</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Possible mechanisms of gender bias in SLE: A new hypothesis involving a comparison of SLE with atopy</article-title>. <source>Lupus</source> <year>2004</year>; <volume>13</volume>: <fpage>217</fpage>–<lpage>222</lpage>.</citation></ref>
<ref id="bibr2-0961203312470184"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jönsen</surname><given-names>A</given-names></name><name><surname>Bengtsson</surname><given-names>AA</given-names></name><name><surname>Nived</surname><given-names>O</given-names></name><name><surname>Truedsson</surname><given-names>L</given-names></name><name><surname>Sturfelt</surname><given-names>G</given-names></name></person-group>. <article-title>Gene-environment interactions in the aetiology of systemic lupus erythematosus</article-title>. <source>Autoimmunity</source> <year>2007</year>; <volume>40</volume>: <fpage>613</fpage>–<lpage>617</lpage>.</citation></ref>
<ref id="bibr3-0961203312470184"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burzynski</surname><given-names>M</given-names></name><name><surname>Duriagin</surname><given-names>S</given-names></name><name><surname>Mostowska</surname><given-names>M</given-names></name><name><surname>Wudarski</surname><given-names>M</given-names></name><name><surname>Chwalinska-Sadowska</surname><given-names>H</given-names></name><name><surname>Jagodzinski</surname><given-names>PP</given-names></name></person-group>. <article-title>MTR 2756 A &gt; G polymorphism is associated with the risk of systemic lupus erythematosus in the Polish population</article-title>. <source>Lupus</source> <year>2007</year>; <volume>16</volume>(<issue>6</issue>): <fpage>450</fpage>–<lpage>454</lpage>.</citation></ref>
<ref id="bibr4-0961203312470184"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harley</surname><given-names>IT</given-names></name><name><surname>Kaufman</surname><given-names>KM</given-names></name><name><surname>Langefeld</surname><given-names>CD</given-names></name><name><surname>Harley</surname><given-names>JB</given-names></name><name><surname>Kelly</surname><given-names>JA</given-names></name></person-group>. <article-title>Genetic susceptibility to SLE: New insights from fine mapping and genome-wide association studies</article-title>. <source>Nat Rev Genet</source> <year>2009</year>; <volume>10</volume>: <fpage>285</fpage>–<lpage>290</lpage>.</citation></ref>
<ref id="bibr5-0961203312470184"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gregersen</surname><given-names>PK</given-names></name><name><surname>Olsson</surname><given-names>LM</given-names></name></person-group>. <article-title>Recent advances in the genetics of autoimmune disease</article-title>. <source>Annu Rev Immunol</source> <year>2009</year>; <volume>27</volume>: <fpage>363</fpage>–<lpage>391</lpage>.</citation></ref>
<ref id="bibr6-0961203312470184"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martens</surname><given-names>HA</given-names></name><name><surname>Nolte</surname><given-names>IM</given-names></name><name><surname>van der Steege</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>An extensive screen of the HLA region reveals an independent association of HLA class I and class II with susceptibility for systemic lupus erythematosus</article-title>. <source>Scand J Rheumatol</source> <year>2009</year>; <volume>38</volume>: <fpage>256</fpage>–<lpage>262</lpage>.</citation></ref>
<ref id="bibr7-0961203312470184"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>B</given-names></name><name><surname>Vyse</surname><given-names>TJ</given-names></name></person-group>. <article-title>The genetics of SLE: An update in the light of genome-wide association studies</article-title>. <source>Rheumatology (Oxford)</source> <year>2008</year>; <volume>47</volume>: <fpage>1603</fpage>–<lpage>1611</lpage>.</citation></ref>
<ref id="bibr8-0961203312470184"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raychaudhuri</surname><given-names>S</given-names></name><name><surname>Remmers</surname><given-names>EF</given-names></name><name><surname>Lee</surname><given-names>AT</given-names></name><etal/></person-group>. <article-title>Common variants at CD40 and other loci confer risk of rheumatoid arthritis</article-title>. <source>Nat Genet</source> <year>2008</year>; <volume>40</volume>: <fpage>1216</fpage>–<lpage>1223</lpage>.</citation></ref>
<ref id="bibr9-0961203312470184"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vazgiourakis</surname><given-names>VM</given-names></name><name><surname>Zervou</surname><given-names>MI</given-names></name><name><surname>Choulaki</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>A common SNP in the CD40 region is associated with systemic lupus erythematosus and correlates with altered CD40 expression: Implications for the pathogenesis</article-title>. <source>Ann Rheum Dis</source> <year>2011</year>; <volume>70</volume>: <fpage>2184</fpage>–<lpage>2190</lpage>.</citation></ref>
<ref id="bibr10-0961203312470184"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paulie</surname><given-names>S</given-names></name><name><surname>Ehlin-Henriksson</surname><given-names>B</given-names></name><name><surname>Mellstedt</surname><given-names>H</given-names></name><name><surname>Koho</surname><given-names>H</given-names></name><name><surname>Ben-Aissa</surname><given-names>H</given-names></name><name><surname>Perlmann</surname><given-names>P</given-names></name></person-group>. <article-title>A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes</article-title>. <source>Cancer Immunol Immunother</source> <year>1985</year>; <volume>20</volume>: <fpage>23</fpage>–<lpage>28</lpage>.</citation></ref>
<ref id="bibr11-0961203312470184"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohkawara</surname><given-names>Y</given-names></name><name><surname>Lim</surname><given-names>KG</given-names></name><name><surname>Xing</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>CD40 expression by human peripheral blood eosinophils</article-title>. <source>J Clin Invest</source> <year>1996</year>; <volume>97</volume>: <fpage>1761</fpage>–<lpage>1766</lpage>.</citation></ref>
<ref id="bibr12-0961203312470184"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Town</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>CD40 is expressed and functional on neuronal cells</article-title>. <source>EMBO J</source> <year>2002</year>; <volume>21</volume>: <fpage>643</fpage>–<lpage>652</lpage>.</citation></ref>
<ref id="bibr13-0961203312470184"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schonbeck</surname><given-names>U</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name></person-group>. <article-title>The CD40/CD154 receptor/ligand dyad</article-title>. <source>Cell Mol Life Sci</source> <year>2001</year>; <volume>58</volume>: <fpage>4</fpage>–<lpage>43</lpage>.</citation></ref>
<ref id="bibr14-0961203312470184"><label>14</label><citation citation-type="other"><comment>Peters AL, Stunz LL, Bishop GA. CD40 and autoimmunity: The dark side of a great activator. <italic>Sem Immunol</italic> 2009; 293–300</comment>.</citation></ref>
<ref id="bibr15-0961203312470184"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Mihara</surname><given-names>M</given-names></name><name><surname>Sinha</surname><given-names>J</given-names></name><name><surname>Davidson</surname><given-names>A</given-names></name></person-group>. <article-title>Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus</article-title>. <source>J Immunol</source> <year>2002</year>; <volume>168</volume>: <fpage>2046</fpage>–<lpage>2053</lpage>.</citation></ref>
<ref id="bibr16-0961203312470184"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boumpas</surname><given-names>DT</given-names></name><name><surname>Furie</surname><given-names>R</given-names></name><name><surname>Manzi</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis</article-title>. <source>Arthritis Rheum</source> <year>2003</year>; <volume>48</volume>: <fpage>719</fpage>–<lpage>727</lpage>.</citation></ref>
<ref id="bibr17-0961203312470184"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>EM</given-names></name><name><surname>Cohen</surname><given-names>AS</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><etal/></person-group>. <article-title>The 1982 revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1982</year>; <volume>25</volume>: <fpage>1271</fpage>–<lpage>1277</lpage>.</citation></ref>
<ref id="bibr18-0961203312470184"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group>. <article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>1725</fpage>–<lpage>1725</lpage>.</citation></ref>
<ref id="bibr19-0961203312470184"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Januchowski</surname><given-names>R</given-names></name><name><surname>Wudarski</surname><given-names>M</given-names></name><name><surname>Chwalińska-Sadowska</surname><given-names>H</given-names></name><name><surname>Jagodzinski</surname><given-names>PP</given-names></name></person-group>. <article-title>Prevalence of ZAP-70, LAT, SLP-76, and DNA methyltransferase 1 expression in CD4+ T cells of patients with systemic lupus erythematosus</article-title>. <source>Clin Rheumatol</source> <year>2008</year>; <volume>27</volume>: <fpage>21</fpage>–<lpage>27</lpage>.</citation></ref>
<ref id="bibr20-0961203312470184"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moulton</surname><given-names>VR</given-names></name><name><surname>Tsokos</surname><given-names>GC</given-names></name></person-group>. <article-title>Abnormalities of T cell signaling in systemic lupus erythematosus</article-title>. <source>Arthritis Res Ther</source> <year>2011</year>; <volume>13</volume>: <fpage>207</fpage>–<lpage>207</lpage>.</citation></ref>
<ref id="bibr21-0961203312470184"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koshy</surname><given-names>M</given-names></name><name><surname>Berger</surname><given-names>D</given-names></name><name><surname>Crow</surname><given-names>MK</given-names></name></person-group>. <article-title>Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes</article-title>. <source>Clin Invest</source> <year>1996</year>; <volume>98</volume>: <fpage>826</fpage>–<lpage>837</lpage>.</citation></ref>
<ref id="bibr22-0961203312470184"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Armitage</surname><given-names>RJ</given-names></name><name><surname>Fanslow</surname><given-names>WC</given-names></name><name><surname>Strockbine</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Molecular and biological characterization of a murine ligand for CD40</article-title>. <source>Nature</source> <year>1992</year>; <volume>357</volume>: <fpage>80</fpage>–<lpage>82</lpage>.</citation></ref>
<ref id="bibr23-0961203312470184"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Néron</surname><given-names>S</given-names></name><name><surname>Nadeau</surname><given-names>PJ</given-names></name><name><surname>Darveau</surname><given-names>A</given-names></name><name><surname>Leblanc</surname><given-names>JF</given-names></name></person-group>. <article-title>Tuning of CD40-CD154 interactions in human B-lymphocyte activation: A broad array of in vitro models for a complex in vivo situation</article-title>. <source>Arch Immunol Ther Exp (Warsz)</source> <year>2011</year>; <volume>59</volume>: <fpage>25</fpage>–<lpage>40</lpage>.</citation></ref>
<ref id="bibr24-0961203312470184"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duffau</surname><given-names>P</given-names></name><name><surname>Seneschal</surname><given-names>J</given-names></name><name><surname>Nicco</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus</article-title>. <source>Sci Transl Med</source> <year>2010</year>; <volume>2</volume>: <fpage>47ra63</fpage>–<lpage>47ra63</lpage>.</citation></ref>
<ref id="bibr25-0961203312470184"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moser</surname><given-names>KL</given-names></name><name><surname>Neas</surname><given-names>BR</given-names></name><name><surname>Salmon</surname><given-names>JE</given-names></name><etal/></person-group>. <article-title>Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees</article-title>. <source>Proc Natl Acad Sci USA</source> <year>1998</year>; <volume>95</volume>: <fpage>14869</fpage>–<lpage>14874</lpage>.</citation></ref>
<ref id="bibr26-0961203312470184"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaffney</surname><given-names>PM</given-names></name><name><surname>Ortmann</surname><given-names>WA</given-names></name><name><surname>Selby</surname><given-names>SA</given-names></name><name><surname>Boumpas</surname><given-names>DT</given-names></name><name><surname>Tosca</surname><given-names>AD</given-names></name><name><surname>Krueger-Krasagakis</surname><given-names>S</given-names></name></person-group>. <article-title>Genome screening in human systemic lupus erythematosus: results from a second Minnesota cohort and combined analyses of 187 sib-pair families</article-title>. <source>Am J Hum Genet</source> <year>2000</year>; <volume>66</volume>: <fpage>547</fpage>–<lpage>556</lpage>.</citation></ref>
<ref id="bibr27-0961203312470184"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toubi</surname><given-names>E</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>. <article-title>The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway</article-title>. <source>Autoimmunity</source> <year>2004</year>; <volume>37</volume>: <fpage>457</fpage>–<lpage>464</lpage>.</citation></ref>
<ref id="bibr28-0961203312470184"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>MF</given-names></name><name><surname>Chao</surname><given-names>SC</given-names></name><name><surname>Wang</surname><given-names>CR</given-names></name><name><surname>Lei</surname><given-names>HY</given-names></name></person-group>. <article-title>Expression of CD40 and CD40 ligand among cell populations within rheumatoid synovial compartment</article-title>. <source>Autoimmunity</source> <year>2001</year>; <volume>34</volume>: <fpage>107</fpage>–<lpage>113</lpage>.</citation></ref>
<ref id="bibr29-0961203312470184"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zervou</surname><given-names>MI</given-names></name><name><surname>Goulielmos</surname><given-names>GN</given-names></name><name><surname>Castro-Giner</surname><given-names>F</given-names></name><name><surname>Boumpas</surname><given-names>DT</given-names></name><name><surname>Tosca</surname><given-names>AD</given-names></name><name><surname>Krueger-Krasagakis</surname><given-names>S</given-names></name></person-group>. <article-title>A CD40 and an NCOA5 gene polymorphism confer susceptibility to psoriasis in a Southern European population: a case-control study</article-title>. <source>Hum Immunol</source> <year>2011</year>; <volume>72</volume>: <fpage>761</fpage>–<lpage>765</lpage>.</citation></ref>
<ref id="bibr30-0961203312470184"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shuang</surname><given-names>C</given-names></name><name><surname>Dalin</surname><given-names>L</given-names></name><name><surname>Weiguang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Association of CD40 gene polymorphisms with sporadic breast cancer in Chinese Han women of Northeast China</article-title>. <source>PLoS One</source> <year>2011</year>; <volume>6</volume>: <fpage>e23762</fpage>–<lpage>e23762</lpage>.</citation></ref>
<ref id="bibr31-0961203312470184"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Hou</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>CD40 gene polymorphisms confer risk of Behcet’s disease but not of Vogt-Koyanagi-Harada syndrome in a Han Chinese population</article-title>. <source>Rheumatology (Oxford)</source> <year>2012</year>; <volume>51</volume>: <fpage>47</fpage>–<lpage>51</lpage>.</citation></ref>
<ref id="bibr32-0961203312470184"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blanco-Kelly</surname><given-names>F</given-names></name><name><surname>Matesanz</surname><given-names>F</given-names></name><name><surname>Alcina</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>CD40: novel association with Crohn’s disease and replication in multiple sclerosis susceptibility</article-title>. <source>PLoS One</source> <year>2010</year>; <volume>5</volume>: <fpage>e11520</fpage>–<lpage>e11520</lpage>.</citation></ref>
<ref id="bibr33-0961203312470184"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ban</surname><given-names>Y</given-names></name><name><surname>Tozaki</surname><given-names>T</given-names></name><name><surname>Taniyama</surname><given-names>M</given-names></name><name><surname>Tomita</surname><given-names>M</given-names></name><name><surname>Ban</surname><given-names>Y</given-names></name></person-group>. <article-title>Association of a C/T single-nucleotide polymorphism in the 5' untranslated region of the CD40 gene with Graves’ disease in Japanese</article-title>. <source>Thyroid</source> <year>2006</year>; <volume>16</volume>: <fpage>443</fpage>–<lpage>446</lpage>.</citation></ref>
<ref id="bibr34-0961203312470184"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodríguez-Rodríguez</surname><given-names>L</given-names></name><name><surname>Castañeda</surname><given-names>S</given-names></name><name><surname>Vázquez-Rodríguez</surname><given-names>TR</given-names></name><etal/></person-group>. <article-title>Influence of CD40 rs1883832 polymorphism in susceptibility to and clinical manifestations of biopsy-proven giant cell arteritis</article-title>. <source>J Rheumatol</source> <year>2010</year>; <volume>37</volume>: <fpage>2076</fpage>–<lpage>2080</lpage>.</citation></ref>
<ref id="bibr35-0961203312470184"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nieters</surname><given-names>A</given-names></name><name><surname>Bracci</surname><given-names>PM</given-names></name><name><surname>de Sanjosé</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>A functional TNFRSF5 polymorphism and risk of non-Hodgkin lymphoma, a pooled analysis</article-title>. <source>Int J Cancer</source> <year>2011</year>; <volume>128</volume>: <fpage>1481</fpage>–<lpage>1485</lpage>.</citation></ref>
<ref id="bibr36-0961203312470184"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>WB</given-names></name><name><surname>Gao</surname><given-names>LB</given-names></name><name><surname>Wang</surname><given-names>YY</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group>. <article-title>Association of CD40 −1C/T polymorphism in the 5'-untranslated region and chronic obstructive pulmonary disease</article-title>. <source>Clin Chim Acta</source> <year>2009</year>; <volume>408</volume>: <fpage>56</fpage>–<lpage>59</lpage>.</citation></ref>
<ref id="bibr37-0961203312470184"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Du</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name></person-group>. <article-title>The relationship between CD40 gene polymorphism and unstable coronary atherosclerotic plaques</article-title>. <source>Clin Cardiol</source> <year>2010</year>; <volume>33</volume>: <fpage>E55</fpage>–<lpage>E60</lpage>.</citation></ref>
<ref id="bibr38-0961203312470184"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burdon</surname><given-names>KP</given-names></name><name><surname>Langefeld</surname><given-names>CD</given-names></name><name><surname>Beck</surname><given-names>SR</given-names></name><etal/></person-group>. <article-title>Variants of the CD40 gene but not of the CD40L gene are associated with coronary artery calcification in the Diabetes Heart Study (DHS)</article-title>. <source>Am Heart J</source> <year>2006</year>; <volume>151</volume>: <fpage>706</fpage>–<lpage>711</lpage>.</citation></ref>
</ref-list>
</back>
</article>